Explore Business Standard
Explore Business Standard
The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.
| Category | Q3 FY25-26 | Q3 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 7,074.48 | 7,072.97 | 0.02 | 27,547.62 | 25,774.09 | 6.88 |
| Expenses | 6,095.33 | 5,084.05 | 19.89 | 20,419.72 | 19,677.86 | 3.77 |
| Other Income | 206.34 | 221.61 | -6.89 | 861.87 | 746.57 | 15.44 |
| Operating Profit | 220.37 | 236.25 | -6.72 | 7,989.77 | 6,842.80 | 16.76 |
| Depreciation | 278.35 | 279.80 | -0.52 | 1,106.95 | 1,051.02 | 5.32 |
| Interest | 14.03 | 14.64 | -4.17 | 62.01 | 89.88 | -31.01 |
| Profit Before Tax | 892.80 | 1,906.96 | -53.18 | 6,820.81 | 5,701.90 | 19.62 |
| Tax | 218.55 | 332.37 | -34.24 | 1,708.35 | 1,696.84 | 0.68 |
| Net Profit | 951.71 | 1,570.51 | -39.40 | 5,291.05 | 4,155.31 | 27.33 |
| Category | Q3 FY25-26 | Q3 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 4,498.08 | 4,970.88 | -9.51 | 19,044.85 | 16,574.34 | 14.91 |
| Expenses | 4,021.25 | 3,309.05 | 21.52 | 13,266.41 | 12,090.19 | 9.73 |
| Other Income | 416.70 | 188.69 | 120.84 | 1,279.38 | 1,433.72 | -10.77 |
| Operating Profit | 3,343.23 | 3,983.78 | -16.08 | 7,057.82 | 5,917.87 | 19.26 |
| Depreciation | 153.33 | 142.62 | 7.51 | 573.89 | 587.59 | -2.33 |
| Interest | 4.03 | 3.55 | 13.52 | 15.11 | 20.25 | -25.38 |
| Profit Before Tax | 736.17 | 1,704.35 | -56.81 | 6,468.82 | 5,310.03 | 21.82 |
| Tax | 119.29 | 266.20 | -55.19 | 1,360.32 | 1,226.69 | 10.89 |
| Net Profit | 616.88 | 1,438.15 | -57.11 | 5,157.65 | 4,077.25 | 26.50 |
| Category | Q3 FY25-26 | Q2 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 7,074.48 | 7,589.44 | -6.79 |
| Expenses | 6,095.33 | 5,694.69 | 7.04 |
| Other Income | 206.34 | 268.95 | -23.28 |
| Operating Profit | 220.37 | 282.13 | -21.89 |
| Depreciation | 278.35 | 296.99 | -6.28 |
| Interest | 14.03 | 13.18 | 6.45 |
| Profit Before Tax | 892.80 | 1,853.83 | -51.84 |
| Tax | 218.55 | 500.46 | -56.33 |
| Net Profit | 951.71 | 1,351.17 | -29.56 |
| Category | Q3 FY25-26 | Q2 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 4,498.08 | 5,225.72 | -13.92 |
| Expenses | 4,021.25 | 3,703.09 | 8.59 |
| Other Income | 416.70 | 254.66 | 63.63 |
| Operating Profit | 3,343.23 | 4,176.76 | -19.96 |
| Depreciation | 153.33 | 141.30 | 8.51 |
| Interest | 4.03 | 2.65 | 52.08 |
| Profit Before Tax | 736.17 | 1,633.34 | -54.93 |
| Tax | 119.29 | 422.81 | -71.79 |
| Net Profit | 616.88 | 1,210.53 | -49.04 |
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Data not available.
| Company | 1 Day | 1 Week | 1 Month | 3 Months | 6 Month | 1 Year |
|---|---|---|---|---|---|---|
| Data Not Found | ||||||
Cipla Ltd has inked an exclusive agreement with Pfizer India to market, distribute, and sell the latter's four brands across the country. Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India, the two companies said in a joint statement on Friday. Pfizer will continue to manufacture, source, and supply these medicines to Cipla for India, they added. It is the first partnership between Pfizer and Cipla in India. The agreement aims to make Pfizer's medicines widely available across India by combining its well-established portfolio with Cipla's deep market reach, the statement said. Pfizer India Country President Meenakshi Nevatia said the partnership with Cipla will help expand the reach of its medicines to patients. "With Pfizer's legacy of breakthroughs, quality and innovation, and
